Use of Saccharomyces boulardii CNCM I-745 as therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury.
Saccharomyces boulardii
enteropathy
intestinal damage
microbiota
nonsteroidal anti-inflammatory drugs
probiotics
Journal
British journal of pharmacology
ISSN: 1476-5381
Titre abrégé: Br J Pharmacol
Pays: England
ID NLM: 7502536
Informations de publication
Date de publication:
12 2023
12 2023
Historique:
revised:
21
02
2023
received:
16
09
2022
accepted:
28
03
2023
medline:
24
11
2023
pubmed:
31
7
2023
entrez:
31
7
2023
Statut:
ppublish
Résumé
Nonsteroidal anti-inflammatory drugs (NSAIDs) can be associated with severe adverse digestive effects. This study examined the protective effects of the probiotic Saccharomyces boulardii CNCM I-745 in a rat model of diclofenac-induced enteropathy. Enteropathy was induced in 40-week-old male rats by intragastric diclofenac (4 mg·kg Diclofenac elicited intestinal damage, along with increments of myeloperoxidase, malondialdehyde, tumour necrosis factor and interleukin-1β, overexpression of TLR2/4, myeloid differentiation primary response 88 (Myd88) and NF-κB p65, increased faecal calprotectin and butyrate levels, and decreased blood haemoglobin levels, occludin and butyrate transporter monocarboxylate transporter 1 (MCT1) expression. In addition, diclofenac provoked a shift of bacterial taxa in both faecal and ileal samples. Treatment with S. boulardii CNCM I-745, in both preventive and curative protocols, counteracted the majority of these deleterious changes. Only preventive administration of the probiotic counteracted NSAID-induced decreased expression of MCT1 and increase in faecal butyrate levels. Occludin expression, after probiotic treatment, did not significantly change. Treatment with S. boulardii CNCM I-745 prevents diclofenac-induced enteropathy through anti-inflammatory and antioxidant activities. Such effects are likely to be related to increased tissue butyrate bioavailability, through an improvement of butyrate uptake by the enteric mucosa.
Sections du résumé
BACKGROUND AND PURPOSE
Nonsteroidal anti-inflammatory drugs (NSAIDs) can be associated with severe adverse digestive effects. This study examined the protective effects of the probiotic Saccharomyces boulardii CNCM I-745 in a rat model of diclofenac-induced enteropathy.
EXPERIMENTAL APPROACH
Enteropathy was induced in 40-week-old male rats by intragastric diclofenac (4 mg·kg
KEY RESULTS
Diclofenac elicited intestinal damage, along with increments of myeloperoxidase, malondialdehyde, tumour necrosis factor and interleukin-1β, overexpression of TLR2/4, myeloid differentiation primary response 88 (Myd88) and NF-κB p65, increased faecal calprotectin and butyrate levels, and decreased blood haemoglobin levels, occludin and butyrate transporter monocarboxylate transporter 1 (MCT1) expression. In addition, diclofenac provoked a shift of bacterial taxa in both faecal and ileal samples. Treatment with S. boulardii CNCM I-745, in both preventive and curative protocols, counteracted the majority of these deleterious changes. Only preventive administration of the probiotic counteracted NSAID-induced decreased expression of MCT1 and increase in faecal butyrate levels. Occludin expression, after probiotic treatment, did not significantly change.
CONCLUSIONS AND IMPLICATIONS
Treatment with S. boulardii CNCM I-745 prevents diclofenac-induced enteropathy through anti-inflammatory and antioxidant activities. Such effects are likely to be related to increased tissue butyrate bioavailability, through an improvement of butyrate uptake by the enteric mucosa.
Substances chimiques
Diclofenac
144O8QL0L1
NF-kappa B
0
Occludin
0
Anti-Inflammatory Agents, Non-Steroidal
0
Butyrates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3215-3233Informations de copyright
© 2023 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
Références
Alexander, S. P., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Beuve, A., Brouckaert, P., Bryant, C., Burnett, J. C., Farndale, R. W., Friebe, A., Garthwaite, J., … Waldman, S. A. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors. British Journal of Pharmacology, 178(S1), S264-S312. https://doi.org/10.1111/bph.15541
Alexander, S. P., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Boison, D., Burns, K. E., Dessauer, C., Gertsch, J., Helsby, N. A., Izzo, A. A., Koesling, D., … Wong, S. S. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Enzymes. British Journal of Pharmacology, 178(S1), S313-S411. https://doi.org/10.1111/bph.15542
Alexander, S. P., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., Southan, C., Davies, J. A., Amarosi, L., Anderson, C. M. H., Beart, P. M., Broer, S., Dawson, P. A., Hagenbuch, B., Hammond, J. R., Inui, K.-I., … Verri, T. (2021). THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Transporters. British Journal of Pharmacology, 178(S1), S412-S513. https://doi.org/10.1111/bph.15543
Alexander, S. P. H., Roberts, R. E., Broughton, B. R. S., Sobey, C. G., George, C. H., Stanford, S. C., Cirino, G., Docherty, J. R., Giembycz, M. A., Hoyer, D., Insel, P. A., Izzo, A. A., Ji, Y., MacEwan, D. J., Mangum, J., Wonnacott, S., & Ahluwalia, A. (2018). Goals and practicalities of immunoblotting and immunohistochemistry: A guide for submission to the British Journal of Pharmacology. British Journal of Pharmacology, 175(3), 407-411. https://doi.org/10.1111/bph.14112
Antonioli, L., Pellegrini, C., Fornai, M., Benvenuti, L., D'Antongiovanni, V., Colucci, R., Bertani, L., di Salvo, C., Semeghini, G., la Motta, C., Giusti, L., Zallocco, L., Ronci, M., Quattrini, L., Angelucci, F., Coviello, V., Oh, W. K., Ha, Q. T. K., Németh, Z. H., … Blandizzi, C. (2021). Preclinical development of FA5, a novel AMP-activated protein kinase (AMPK) activator as an innovative drug for the management of bowel inflammation. International Journal of Molecular Sciences, 22, 6325. https://doi.org/10.3390/ijms22126325
Arthur, J. C., Perez-Chanona, E., Mühlbauer, M., Tomkovich, S., Uronis, J. M., Fan, T. J., Campbell, B. J., Abujamel, T., Dogan, B., Rogers, A. B., Rhodes, J. M., Stintzi, A., Simpson, K. W., Hansen, J. J., Keku, T. O., Fodor, A. A., & Jobin, C. (2012). Intestinal inflammation targets cancer-inducing activity of the microbiota. Science, 338, 120-123. https://doi.org/10.1126/science.1224820
Bjarnason, I., Hayllar, J., Smethurst, P., Price, A., & Gumpel, M. J. (1992). Metronidazole reduces intestinal inflammation and blood loss in non-steroidal anti-inflammatory drug induced enteropathy. Gut, 33, 1204-1208. https://doi.org/10.1136/gut.33.9.1204
Bjarnason, I., & Rainsford, K. D. (2021). NSAID-enteropathy and intestinal microbes. Inflammopharmacology, 29, 1-4. https://doi.org/10.1007/s10787-020-00766-8
Bjarnason, I., Scarpignato, C., Holmgren, E., Olszewski, M., Rainsford, K. D., & Lanas, A. (2018). Mechanisms of damage to the gastrointestinal tract from nonsteroidal anti-inflammatory drugs. Gastroenterology, 154, 500-514. https://doi.org/10.1053/j.gastro.2017.10.049
Briand, F., Sulpice, T., Giammarinaro, P., & Roux, X. (2019). Saccharomyces boulardii CNCM I-745 changes lipidemic profile and gut microbiota in a hamster hypercholesterolemic model. Beneficial Microbes, 10, 555-567. https://doi.org/10.3920/BM2018.0134
Chen, J., & Vitetta, L. (2020). The role of butyrate in attenuating pathobiont-induced hyperinflammation. Immune Netw, 20, e15. https://doi.org/10.4110/in.2020.20.e15
Chen, X., Gao, F., & Zhang, L. (2022). Lactobacillus complex capsules ameliorate aspirin-related small intestinal mucosal injury: A prospective, randomized, controlled clinical trial. Scandinavian Journal of Gastroenterology, 57, 1195-1201. https://doi.org/10.1080/00365521.2022.2073184
Chen, X., Yang, G., Song, J. H., Xu, H., Li, D., Goldsmith, J., Zeng, H., Parsons-Wingerter, P. A., Reinecker, H. C., & Kelly, C. P. (2013). Probiotic yeast inhibits VEGFR signaling and angiogenesis in intestinal inflammation. PLoS ONE, 8, e64227. https://doi.org/10.1371/journal.pone.0064227
Choi, S. I., Son, J. H., Kim, N., Kim, Y. S., Nam, R. H., Park, J. H., Song, C. H., Yu, J. E., Lee, D. H., Yoon, K., Min, H., Kim, Y. R., & Seok, Y. J. (2021). Changes in cecal microbiota and short-chain fatty acid during lifespan of the rat. Journal of Neurogastroenterology and Motility, 27, 134-146. https://doi.org/10.5056/jnm20148
Colucci, R., Pellegrini, C., Fornai, M., Tirotta, E., Antonioli, L., Renzulli, C., Ghelardi, E., Piccoli, E., Gentile, D., Benvenuti, L., Natale, G., Fulceri, F., Palazón-Riquelme, P., López-Castejón, G., Blandizzi, C., & Scarpignato, C. (2018). Pathophysiology of NSAID-associated intestinal lesions in the rat: Luminal bacteria and mucosal inflammation as targets for prevention. Frontiers in Pharmacology, 9, 1340. https://doi.org/10.3389/fphar.2018.01340
Cristofori, F., Dargenio, V. N., Dargenio, C., Miniello, V. L., Barone, M., & Francavilla, R. (2021). Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: A door to the body. Frontiers in Immunology, 12, 578386.
Curtis, M. J., Alexander, S. P. H., Cirino, G., George, C. H., Kendall, D. A., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Patel, H. H., Sobey, C. G., Stanford, S. C., Stanley, P., Stefanska, B., Stephens, G. J., Teixeira, M. M., Vergnolle, N., & Ahluwalia, A. (2022). Planning experiments: Updated guidance on experimental design and analysis and their reporting III. British Journal of Pharmacology, 179, 3907-3913. https://doi.org/10.1111/bph.15868
Czerucka, D., Piche, T., & Rampal, P. (2007). Review article: Yeast as probiotics-Saccharomyces boulardii. Alimentary Pharmacology & Therapeutics, 26, 767-778. https://doi.org/10.1111/j.1365-2036.2007.03442.x
D'Antongiovanni, V., Pellegrini, C., Benvenuti, L., Fornai, M., Di Salvo, C., Natale, G., Ryskalin, L., Bertani, L., Lucarini, E., Di Cesare Mannelli, L., Ghelardini, C., Nemeth, Z. H., Haskó, G., & Antonioli, L. (2022). Anti-inflammatory effects of novel P2X4 receptor antagonists, NC-2600 and NP-1815-PX, in a murine model of colitis. Inflammation, 45, 1829-1847. https://doi.org/10.1007/s10753-022-01663-8
D'Antongiovanni, V., Pellegrini, C., Antonioli, L., Benvenuti, L., Di Salvo, C., Flori, L., Piccarducci, R., Daniele, S., Martelli, A., Calderone, V., Martini, C., & Fornai, M. (2021). Palmitoylethanolamide counteracts enteric inflammation and bowel motor dysfunctions in a mouse model of Alzheimer's disease. Frontiers in Pharmacology, 12, 748021. https://doi.org/10.3389/fphar.2021.748021
De Preter, V., Arijs, I., Windey, K., Vanhove, W., Vermeire, S., Schuit, F., Rutgeerts, P., & Verbeke, K. (2012). Impaired butyrate oxidation in ulcerative colitis is due to decreased butyrate uptake and a defect in the oxidation pathway. Inflammatory Bowel Diseases, 18, 1127-1136. https://doi.org/10.1002/ibd.21894
Endo, H., Higurashi, T., Hosono, K., Sakai, E., Sekino, Y., Iida, H., Sakamoto, Y., Koide, T., Takahashi, H., Yoneda, M., Tokoro, C., Inamori, M., Abe, Y., & Nakajima, A. (2011). Efficacy of Lactobacillus casei treatment on small bowel injury in chronic low-dose aspirin users: A pilot randomized controlled study. Journal of Gastroenterology, 46, 894-905. https://doi.org/10.1007/s00535-011-0410-1
Engel, S., Mortensen, B., Wellejus, A., VeraJimenez, N., Struve, C., Brummer, R. J., Damholt, A., Woods, T., & Shanahan, F. (2022). Safety of Bifidobacterium breve, Bif195, employing a human exercise-induced intestinal permeability model: A randomised, double-blinded, placebo-controlled, parallel group trial. Beneficial Microbes, 13, 243-252. https://doi.org/10.3920/BM2021.0173
Fornai, M., Antonioli, L., Colucci, R., Pellegrini, C., Giustarini, G., Testai, L., Martelli, A., Matarangasi, A., Natale, G., Calderone, V., Tuccori, M., Scarpignato, C., & Blandizzi, C. (2014). NSAID-induced enteropathy: Are the currently available selective COX-2 inhibitors all the same? The Journal of Pharmacology and Experimental Therapeutics, 348, 86-95. https://doi.org/10.1124/jpet.113.207118
Fornai, M., Antonioli, L., Pellegrini, C., Colucci, R., Sacco, D., Tirotta, E., Natale, G., Bartalucci, A., Flaibani, M., Renzulli, C., Ghelardi, E., Blandizzi, C., & Scarpignato, C. (2016). Small bowel protection against NSAID-injury in rats: Effect of rifaximin, a poorly absorbed, GI targeted, antibiotic. Pharmacological Research, 104, 186-196. https://doi.org/10.1016/j.phrs.2015.12.031
Fornai, M., Pellegrini, C., Benvenuti, L., Tirotta, E., Gentile, D., Natale, G., Ryskalin, L., Colucci, R., Piccoli, E., Ghelardi, E., Blandizzi, C., & Antonioli, L. (2020). Protective effects of the combination Bifidobacterium longum plus lactoferrin against NSAID-induced enteropathy. Nutrition, 70, 110583. https://doi.org/10.1016/j.nut.2019.110583
Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., Takahashi, M., Fukuda, N. N., Murakami, S., Miyauchi, E., Hino, S., Atarashi, K., Onawa, S., Fujimura, Y., Lockett, T., … Ohno, H. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504, 446-450. https://doi.org/10.1038/nature12721
Gao, H., Li, Y., Sun, J., Xu, H., Wang, M., Zuo, X., Fu, Q., Guo, Y., Chen, Z., Zhang, P., Li, X., Wang, N., Ye, T., & Yao, Y. (2021). Saccharomyces boulardii ameliorates dextran sulfate sodium-induced ulcerative colitis in mice by regulating NF-κB and Nrf2 signaling pathways. Oxidative Medicine and Cellular Longevity, 2021, 1622375. https://doi.org/10.1155/2021/1622375
Girard, P., Pansart, Y., & Verleye, M. (2014). Anti-hypercholesterolemic effect of Saccharomyces boulardii in the hamster. Pharmacology, 94, 239-244. https://doi.org/10.1159/000365009
Gotteland, M., Cruchet, S., & Verbeke, S. (2001). Effect of Lactobacillus ingestion on the gastrointestinal mucosal barrier alterations induced by indometacin in humans. Alimentary Pharmacology & Therapeutics, 15, 11-17. https://doi.org/10.1046/j.1365-2036.2001.00898.x
Huang, X., Oshima, T., Tomita, T., Fukui, H., & Miwa, H. (2021). Butyrate alleviates cytokine-induced barrier dysfunction by modifying claudin-2 levels. Biology (Basel), 10, 205. https://doi.org/10.3390/biology10030205
Jiang, S., Cai, L., Lv, L., & Li, L. (2021). Pediococcus pentosaceus, a future additive or probiotic candidate. Microbial Cell Factories, 20, 45. https://doi.org/10.1186/s12934-021-01537-y
Lai, Y., Zhong, W., Yu, T., Xia, Z. S., Li, J. Y., Ouyang, H., Shan, T. D., Yang, H. S., & Chen, Q. K. (2015). Rebamipide promotes the regeneration of aspirin-induced small-intestine mucosal injury through accumulation of β-catenin. PLoS ONE, 10, e0132031. https://doi.org/10.1371/journal.pone.0132031
Lanas, A., García-Rodríguez, L. A., Polo-Tomás, M., Ponce, M., Alonso-Abreu, I., Perez-Aisa, M. A., Perez-Gisbert, J., Bujanda, L., Castro, M., Muñoz, M., Rodrigo, L., Calvet, X., del-Pino, D., & Garcia, S. (2009). Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. The American Journal of Gastroenterology, 104, 1633-1641. https://doi.org/10.1038/ajg.2009.164
Lanas, Á., & Scarpignato, C. (2006). Microbial flora in NSAID-induced intestinal damage: A role for antibiotics? Digestion, 73(Suppl 1), 136-150. https://doi.org/10.1159/000089789
Leite, A. Z. A., Sipahi, A. M., Damião, A. O. M. C., Coelho, A. M. M., Garcez, A. T., Machado, M. C. C., Buchpiguel, C. A., Lopasso, F. P., Lordello, M. L., Agostinho, C. L., & Laudanna, A. A. (2001). Protective effect of metronidazole on uncoupling mitochondrial oxidative phosphorylation induced by NSAID: A new mechanism. Gut, 48, 163-167. https://doi.org/10.1136/gut.48.2.163
Liang, X., Bittinger, K., Li, X., Abernethy, D. R., Bushman, F. D., & FitzGerald, G. A. (2015). Bidirectional interactions between indomethacin and the murine intestinal microbiota. eLife, 4, e08973. https://doi.org/10.7554/eLife.08973
Lilley, E., Stanford, S. C., Kendall, D. E., Alexander, S. P., Cirino, G., Docherty, J. R., George, C. H., Insel, P. A., Izzo, A. A., Ji, Y., Panettieri, R. A., Sobey, C. G., Stefanska, B., Stephens, G., Teixeira, M., & Ahluwalia, A. (2020). ARRIVE 2.0 and the British Journal of Pharmacology: Updated guidance for 2020. British Journal of Pharmacology, 177(16), 3611-3616. https://doi.org/10.1111/bph.15178
Lim, D. H., Jung, K., Lee, S. B., Park, I. K., Cha, H. J., Park, J. H., Kim, B. G., Jung, S. W., Jeong, D., Kim, J. H., Kim, S. E., Moon, W., Park, M., & Park, S. J. (2020). Non-steroidal anti-inflammatory drug-induced enteropathy as a major risk factor for small bowel bleeding: A retrospective study. BMC Gastroenterology, 20, 178. https://doi.org/10.1186/s12876-020-01329-5
Mahnic, A., Breskvar, M., Dzeroski, S., Skok, P., Pintar, S., & Rupnik, M. (2020). Distinct types of gut microbiota dysbiosis in hospitalized gastroenterological patients are disease non-related and characterized with the predominance of either Enterobacteriaceae or Enterococcus. Frontiers in Microbiology, 11, 120. https://doi.org/10.3389/fmicb.2020.00120
Montalto, M., Gallo, A., Curigliano, V., D'Onofrio, F., Santoro, L., Covino, M., Dalvai, S., Gasbarrini, A., & Gasbarrini, G. (2010). Clinical trial: The effects of a probiotic mixture on non-steroidal anti-inflammatory drug enteropathy-A randomized, double-blind, cross-over, placebo-controlled study. Alimentary Pharmacology & Therapeutics, 32, 209-214. https://doi.org/10.1111/j.1365-2036.2010.04324.x
Mortensen, B., Murphy, C., O'Grady, J., Lucey, M., Elsafi, G., Barry, L., Westphal, V., Wellejus, A., Lukjancenko, O., Eklund, A. C., Nielsen, H. B., Baker, A., Damholt, A., van Hylckama Vlieg, J. E. T., Shanahan, F., & Buckley, M. (2019). Bifidobacterium breve Bif195 protects against small-intestinal damage caused by acetylsalicylic acid in healthy volunteers. Gastroenterology, 157, 637-646.e4. https://doi.org/10.1053/j.gastro.2019.05.008
Mumy, K. L., Chen, X., Kelly, C. P., & McCormick, B. A. (2008). Saccharomyces boulardii interferes with Shigella pathogenesis by postinvasion signaling events. American Journal of Physiology. Gastrointestinal and Liver Physiology, 294, G599-G609. https://doi.org/10.1152/ajpgi.00391.2007
Ocón, B., Anzola, A., Ortega-González, M., Zarzuelo, A., Suárez, M. D., Sánchez de Medina, F., & Martínez-Augustin, O. (2013). Active hexose-correlated compound and Bifidobacterium longum BB536 exert symbiotic effects in experimental colitis. European Journal of Nutrition, 52, 457-466. https://doi.org/10.1007/s00394-012-0347-z
Pais, P., Almeida, V., Yılmaz, M., & Teixeira, M. C. (2020). Saccharomyces boulardii: What makes it tick as successful probiotic? Journal of Fungi, 6, 1-15.
Parada Venegas, D., De la Fuente, M. K., Landskron, G., González, M. J., Quera, R., Dijkstra, G., Harmsen, H. J., Faber, K. N., & Hermoso, M. A. (2019). Short chain fatty acids (SCFAs)-mediated gut epithelial and immune regulation and its relevance for inflammatory bowel diseases. Frontiers in Immunology, 10, 277.
Pellegrini, C., D'Antongiovanni, V., Miraglia, F., Rota, L., Benvenuti, L., Di Salvo, C., Testa, G., Capsoni, S., Carta, G., Antonioli, L., Cattaneo, A., Blandizzi, C., Colla, E., & Fornai, M. (2022). Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson's disease before brain pathology. Npj Parkinson's Disease, 8, 9. https://doi.org/10.1038/s41531-021-00263-x
Pellegrini, C., Daniele, S., Antonioli, L., Benvenuti, L., D'Antongiovanni, V., Piccarducci, R., Pietrobono, D., Citi, V., Piragine, E., Flori, L., Ippolito, C., Segnani, C., Palazon-Riquelme, P., Lopez-Castejon, G., Martelli, A., Colucci, R., Bernardini, N., Trincavelli, M. L., Calderone, V., … Fornai, M. (2020). Prodromal intestinal events in Alzheimer's disease (AD): Colonic dysmotility and inflammation are associated with enteric ad-related protein deposition. International Journal of Molecular Sciences, 21, 3523. https://doi.org/10.3390/ijms21103523
Pellegrini, C., Fornai, M., Benvenuti, L., Colucci, R., Caputi, V., Palazon-Riquelme, P., Giron, M. C., Nericcio, A., Garelli, F., D'Antongiovanni, V., Segnani, C., Ippolito, C., Nannipieri, M., Lopez-Castejon, G., Pelegrin, P., Haskó, G., Bernardini, N., Blandizzi, C., & Antonioli, L. (2021). NLRP3 at the crossroads between immune/inflammatory responses and enteric neuroplastic remodeling in a mouse model of diet-induced obesity. British Journal of Pharmacology, 178, 3924-3942. https://doi.org/10.1111/bph.15532
Pellegrini, C., Fornai, M., Colucci, R., Benvenuti, L., D'Antongiovanni, V., Natale, G., Fulceri, F., Giorgis, M., Marini, E., Gastaldi, S., Bertinaria, M., Blandizzi, C., & Antonioli, L. (2018). A comparative study on the efficacy of NLRP3 inflammasome signaling inhibitors in a pre-clinical model of bowel inflammation. Frontiers in Pharmacology, 9, 1405. https://doi.org/10.3389/fphar.2018.01405
Percie du Sert, N., Hurst, V., Ahluwalia, A., Alam, S., Avey, M. T., Baker, M., Browne, W. J., Clark, A., Cuthill, I. C., Dirnagl, U., Emerson, M., Garner, P., Holgate, S. T., Howells, D. W., Karp, N. A., Lazic, S. E., Lidster, K., MacCallum, C. J., Macleod, M., … Würbel, H. (2020). The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research. PLoS Biology, 18(7), e3000410. https://doi.org/10.1371/journal.pbio.3000410
Pereira-Leite, C., Nunes, C., Jamal, S. K., Cuccovia, I. M., & Reis, S. (2017). Nonsteroidal anti-inflammatory therapy: A journey toward safety. Medicinal Research Reviews, 37, 802-859. https://doi.org/10.1002/med.21424
Pothoulakis, C. (2009). Review article: Anti-inflammatory mechanisms of action of Saccharomyces boulardii. Alimentary Pharmacology & Therapeutics, 30, 826-833. https://doi.org/10.1111/j.1365-2036.2009.04102.x
Roy Sarkar, S., Mitra Mazumder, P., Chatterjee, K., Sarkar, A., Adhikary, M., Mukhopadhyay, K., & Banerjee, S. (2021). Saccharomyces boulardii ameliorates gut dysbiosis associated cognitive decline. Physiology & Behavior, 236, 113411. https://doi.org/10.1016/j.physbeh.2021.113411
Satoh, H., & Takeuchi, K. (2012). Management of NSAID/aspirin-induced small intestinal damage by GI-sparing NSAIDs, anti-ulcer drugs and food constituents. Current Medicinal Chemistry, 19, 82-89. https://doi.org/10.2174/092986712803413980
Scarpignato, C., & Bjarnason, I. (2019). Drug-induced small bowel injury: A challenging and often forgotten clinical condition. Current Gastroenterology Reports, 21, 55. https://doi.org/10.1007/s11894-019-0726-1
Scarpignato, C., Lanas, A., Blandizzi, C., Lems, W. F., Hermann, M., & Hunt, R. H. (2015). Safe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis-An expert consensus addressing benefits as well as gastrointestinal and cardiovascular risks. BMC Medicine, 13, 55. https://doi.org/10.1186/s12916-015-0285-8
Soyturk, M., Saygili, S. M., Baskin, H., Sagol, O., Yilmaz, O., Saygili, F., & Akpinar, H. (2012). Effectiveness of Saccharomyces boulardii in a rat model of colitis. World Journal of Gastroenterology, 18, 6452-6460. https://doi.org/10.3748/wjg.v18.i44.6452
Suzuki, T., Masui, A., Nakamura, J., Shiozawa, H., Aoki, J., Nakae, H., Tsuda, S., Imai, J., Hideki, O., Matsushima, M., Mine, T., Tamura, A., Ohtsu, T., Asami, Y., & Takagi, A. (2017). Yogurt containing Lactobacillus gasseri mitigates aspirin-induced small bowel injuries: A prospective, randomized, double-blind, placebo-controlled trial. Digestion, 95, 49-54. https://doi.org/10.1159/000452361
Svistunov, A. A., Osadchuk, M. A., Kireeva, N. V., Hudarova, A. A., & Achkasov, E. E. (2018). NSAID-induced enteropathy: The current state of the problem. Terapevticheskiĭ Arkhiv, 90, 95-100. https://doi.org/10.26442/terarkh201890895-100
Thibault, R., De Coppet, P., Daly, K., Bourreille, A., Cuff, M., Bonnet, C., Mosnier, J.-. F., Galmiche, J.-. P., Shirazi-Beechey, S., & Segain, J.-. P. (2007). Down-regulation of the monocarboxylate transporter 1 is involved in butyrate deficiency during intestinal inflammation. Gastroenterology, 133, 1916-1927. https://doi.org/10.1053/j.gastro.2007.08.041
Villodre Tudela, C., Boudry, C., Stumpff, F., Aschenbach, J. R., Vahjen, W., Zentek, J., & Pieper, R. (2015). Down-regulation of monocarboxylate transporter 1 (MCT1) gene expression in the colon of piglets is linked to bacterial protein fermentation and pro-inflammatory cytokine-mediated signalling. The British Journal of Nutrition, 113, 610-617. https://doi.org/10.1017/S0007114514004231
Wallace, J. L. (2013). Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy. World Journal of Gastroenterology, 19, 1861-1876. https://doi.org/10.3748/wjg.v19.i12.1861
Wang, X., Tang, Q., Hou, H., Zhang, W., Li, M., Chen, D., Gu, Y., Wang, B., Hou, J., Liu, Y., & Cao, H. (2021). Gut microbiota in NSAID enteropathy: New insights from inside. Frontiers in Cellular and Infection Microbiology, 11, 679396. https://doi.org/10.3389/fcimb.2021.679396
Watanabe, T., Fujiwara, Y., & Chan, F. K. L. (2020). Current knowledge on non-steroidal anti-inflammatory drug-induced small-bowel damage: A comprehensive review. Journal of Gastroenterology, 55, 481-495. https://doi.org/10.1007/s00535-019-01657-8
Yoshihara, T., Oikawa, Y., Kato, T., Kessoku, T., Kobayashi, T., Kato, S., Misawa, N., Ashikari, K., Fuyuki, A., Ohkubo, H., Higurashi, T., Tateishi, Y., Tanaka, Y., Nakajima, S., Ohno, H., Wada, K., & Nakajima, A. (2020). The protective effect of Bifidobacterium bifidum G9-1 against mucus degradation by Akkermansia muciniphila following small intestine injury caused by a proton pump inhibitor and aspirin. Gut Microbes, 11, 1385-1404. https://doi.org/10.1080/19490976.2020.1758290
Zhang, J., Song, L., Wang, Y., Liu, C., Zhang, L., Zhu, S., Liu, S., & Duan, L. (2019). Beneficial effect of butyrate-producing Lachnospiraceae on stress-induced visceral hypersensitivity in rats. Journal of Gastroenterology and Hepatology, 34, 1368-1376. https://doi.org/10.1111/jgh.14536
Zhang, M., Xia, F., Xia, S., Zhou, W., Zhang, Y., Han, X., Zhao, K., Feng, L., Dong, R., Tian, D., Yu, Y., & Liao, J. (2022). NSAID-associated small intestinal injury: An overview from animal model development to pathogenesis, treatment, and prevention. Frontiers in Pharmacology, 13, 818877. https://doi.org/10.3389/fphar.2022.818877